<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>House of Commons Science and Technology Committee Inquiry into Blood, Tissue and Organ Screening and vCJD</title></head><body><div><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written Evidence submitted by </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">UK Blood Services Joint Professional Advisory Committee (BTO0030)</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Overview</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 41.6pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">This paper is intended to describe the </span><span style="font-family:'Times New Roman'; font-size:11pt">overall approach</span><span style="font-family:'Times New Roman'; font-size:11pt"> to the </span><span style="font-family:'Times New Roman'; font-size:11pt">safety</span><span style="font-family:'Times New Roman'; font-size:11pt"> of blood, tissues and stem cells provided by the four UK Blood Services, the</span><span style="font-family:'Times New Roman'; font-size:11pt">ir</span><span style="font-family:'Times New Roman'; font-size:11pt"> legal framework and advisory arrangements</span><span style="font-family:'Times New Roman'; font-size:11pt">. This is followed by</span><span style="font-family:'Times New Roman'; font-size:11pt"> an overview of key donor selection and testing policies, residual risks of blood co</span><span style="font-family:'Times New Roman'; font-size:11pt">mponents, </span><span style="font-family:'Times New Roman'; font-size:11pt">and the role of </span><span style="font-family:'Times New Roman'; font-size:11pt">haemovigilance and </span><span style="font-family:'Times New Roman'; font-size:11pt">horizon scanning </span><span style="font-family:'Times New Roman'; font-size:11pt">in the identification of</span><span style="font-family:'Times New Roman'; font-size:11pt"> new threats</span><span style="font-family:'Times New Roman'; font-size:11pt">. Finally</span><span style="font-family:'Times New Roman'; font-size:11pt">, strategies to ensure that blood is used appropriately</span><span style="font-family:'Times New Roman'; font-size:11pt"> are discussed</span><span style="font-family:'Times New Roman'; font-size:11pt">, along with</span><span style="font-family:'Times New Roman'; font-size:11pt"> a summary </span><span style="font-family:'Times New Roman'; font-size:11pt">of the current blood supply situation.</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Provision of bl</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">ood components in the United Kingdom</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="2" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 41.6pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Blood in the UK is provided by the four Blood Services of each home nation (NHS Blood and Transplant, Welsh Blood Service, Scottish National Blood Transfusion Service, and Northern Ireland Blood Transfusion Service), each accountable to their Department of</span><span style="font-family:'Times New Roman'; font-size:11pt"> Health.  </span><span style="font-family:'Times New Roman'; font-size:11pt">2.2 million whole blood donations are made each year in the United Kingdom.  These donations are separated into a variety of components, namely – red cells, platelets, fresh frozen plasma and cryoprecipitate.  Red cells replace oxygen carrying ca</span><span style="font-family:'Times New Roman'; font-size:11pt">pacity in patients with low haemoglobin (anaemia) or reduced circulating blood volume </span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">g</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> due to haemorrhage</span><span style="font-family:'Times New Roman'; font-size:11pt">.  Platelets are involved in the initial stages of blood clotting - platelet transfusions are used to correct low platelet levels (thrombocytopenia</span><span style="font-family:'Times New Roman'; font-size:11pt">) related to bone marrow suppression (for example due to chemotherapy for treatment of malignancy) or </span><span style="font-family:'Times New Roman'; font-size:11pt">due </span><span style="font-family:'Times New Roman'; font-size:11pt">to dilution or consumption of platelets </span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">g</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">following serious trauma.  Fresh frozen plasma is used to correct multiple coagulation factor deficiencie</span><span style="font-family:'Times New Roman'; font-size:11pt">s and cryoprecipitate </span><span style="font-family:'Times New Roman'; font-size:11pt">is </span><span style="font-family:'Times New Roman'; font-size:11pt">specifically to correct deficiencies of fibrinogen - again m</span><span style="font-family:'Times New Roman'; font-size:11pt">ainly in the context of </span><span style="font-family:'Times New Roman'; font-size:11pt">massive haemorrhage or trauma.  In many cases</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> blood components may be directly life saving or life enhancing</span><span style="font-family:'Times New Roman'; font-size:11pt">;</span><span style="font-family:'Times New Roman'; font-size:11pt"> at other times they permit life-savi</span><span style="font-family:'Times New Roman'; font-size:11pt">ng interventions which otherwise would not be possible (fo</span><span style="font-family:'Times New Roman'; font-size:11pt">r example</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> liver </span><span style="font-family:'Times New Roman'; font-size:11pt">or bone marrow transplantation).</span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="3" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 41.6pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In addition to manufacture from whole blood donations, platelets can also be collected as a single component by a technique called apheresis (or co</span><span style="font-family:'Times New Roman'; font-size:11pt">mponent donation), which involves separation of the platelets during donation, and return of red cells to the donor.  </span><span style="font-family:'Times New Roman'; font-size:11pt">This allows more frequent donation than whole blood.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Regulatory and policy-making arrangements</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="4" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 41.6pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The legal underpinning provision of bloo</span><span style="font-family:'Times New Roman'; font-size:11pt">d components in the UK </span><span style="font-family:'Times New Roman'; font-size:11pt">derives from EU Blood Directive</span><span style="font-family:'Times New Roman'; font-size:11pt"> 2002/98/EC and its daughter Directives </span><span style="font-family:'Times New Roman'; font-size:11pt">transposed into UK law as the Blood Safety and Quality Regulations </span><span style="font-family:'Times New Roman'; font-size:11pt">(BSQR)</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">2005</span><span style="font-family:'Times New Roman'; font-size:11pt">. Blood components (red cells, platelets and plasma for direct clinical use) are not</span><span style="font-family:'Times New Roman'; font-size:11pt"> licenced medicinal</span><span style="font-family:'Times New Roman'; font-size:11pt"> product</span><span style="font-family:'Times New Roman'; font-size:11pt">s, but each Blood Service is licenced by the </span><span style="font-family:'Times New Roman'; font-size:11pt">Medicines and Healthcare products Regulatory Agency (</span><span style="font-family:'Times New Roman'; font-size:11pt">MHRA</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">, and subject to regular inspection.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="5" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 41.6pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Links to EU regulation and legislation are provided </span><span style="font-family:'Times New Roman'; font-size:11pt">on behalf of the Secretary of State</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">by </span><span style="font-family:'Times New Roman'; font-size:11pt">the MHRA, who </span><span style="font-family:'Times New Roman'; font-size:11pt">lead for</span><span style="font-family:'Times New Roman'; font-size:11pt"> the UK </span><span style="font-family:'Times New Roman'; font-size:11pt">on negotiating EU legislation on the regulation of medicines</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> including blood</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> within the European Commission</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt 0pt 0pt 10.35pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="6" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 41.6pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">For tissues and cells, the corresponding EU </span><span style="font-family:'Times New Roman'; font-size:11pt">Tissues and Cells </span><span style="font-family:'Times New Roman'; font-size:11pt">Directive </span><span style="font-family:'Times New Roman'; font-size:11pt">2004/23/EC</span><span style="font-family:'Times New Roman'; font-size:11pt"> was transposed as the Human Tissue </span><span style="font-family:'Times New Roman'; font-size:11pt">(Quality and Safety </span><span style="font-family:'Times New Roman'; font-size:11pt">Act</span><span style="font-family:'Times New Roman'; font-size:11pt"> for Human Application) Regulation 2007</span><span style="font-family:'Times New Roman'; font-size:11pt">. All providers of tissues and cells are licenced </span><span style="font-family:'Times New Roman'; font-size:11pt">and inspected </span><span style="font-family:'Times New Roman'; font-size:11pt">by the Human Tissue Authority</span><span style="font-family:'Times New Roman'; font-size:11pt"> (HTA)</span><span style="font-family:'Times New Roman'; font-size:11pt">.   </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="7" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 41.6pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Policies governing donor selection, testing and manuf</span><span style="font-family:'Times New Roman'; font-size:11pt">acturing are UK-wide.  </span><span style="font-family:'Times New Roman'; font-size:11pt">On certain topics of high public interest e</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">g</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> vCJD and donation by men who have had sex with men</span><span style="font-family:'Times New Roman'; font-size:11pt"> (MSM)</span><span style="font-family:'Times New Roman'; font-size:11pt">, and </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">introduction of any new screening test, </span><span style="font-family:'Times New Roman'; font-size:11pt">policies are considered by </span><span style="font-family:'Times New Roman'; font-size:11pt">the Advisory Committee on the Safety of Blood, </span><span style="font-family:'Times New Roman'; font-size:11pt">Tissues and Organs (</span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">, and recommendations made to Health Ministers </span><span style="font-family:'Times New Roman'; font-size:11pt">and</span><span style="font-family:'Times New Roman'; font-size:11pt"> the 4 UK Departments of Health.  However, there are many operational </span><span style="font-family:'Times New Roman'; font-size:11pt">Blood Service </span><span style="font-family:'Times New Roman'; font-size:11pt">policies </span><span style="font-family:'Times New Roman'; font-size:11pt">which must </span><span style="font-family:'Times New Roman'; font-size:11pt">also be consistent across the </span><span style="font-family:'Times New Roman'; font-size:11pt">UK. This is achieved through the UK Blood Serv</span><span style="font-family:'Times New Roman'; font-size:11pt">ices Joint Professional Advisory Committee (JPAC), which </span><span style="font-family:'Times New Roman'; font-size:11pt">is supported by </span><span style="font-family:'Times New Roman'; font-size:11pt">7</span><span style="font-family:'Times New Roman'; font-size:11pt"> Standing Advisory Committees, and which </span><span style="font-family:'Times New Roman'; font-size:11pt">reports to the UK Blood Services </span><span style="font-family:'Times New Roman'; font-size:11pt">Forum (</span><span style="font-family:'Times New Roman'; font-size:11pt">Chief Executives</span><span style="font-family:'Times New Roman'; font-size:11pt"> and Medical Directors). JPAC membership</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">also includes MHRA, </span><span style="font-family:'Times New Roman'; font-size:11pt">HTA, </span><span style="font-family:'Times New Roman'; font-size:11pt">the National Instit</span><span style="font-family:'Times New Roman'; font-size:11pt">ute for Biological Standards and Control, and Public Health England. </span><span style="font-family:'Times New Roman'; font-size:11pt">The key outputs of JPAC are Donor Selection Guidelines for Blood</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> Tissues</span><span style="font-family:'Times New Roman'; font-size:11pt"> and Cells (bone marrow, haemopoietic stem cells and cord blood)</span><span style="font-family:'Times New Roman'; font-size:11pt">, Guidelines for UK Blood Services, a Handbook of </span><span style="font-family:'Times New Roman'; font-size:11pt">Transfusion Medicine</span><span style="font-family:'Times New Roman'; font-size:11pt"> (</span><span style="font-family:'Times New Roman'; font-size:11pt">sent to </span><span style="font-family:'Times New Roman'; font-size:11pt">hospitals through the four Blood Services</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt">, and position statements on key topics.  See website </span><a href="http://www.transfusionguidelines.org"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">www.transfusionguidelines.org</span></a><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">  JPAC also has a system for rapid modification</span><span style="font-family:'Times New Roman'; font-size:11pt"> of guidance for deferral/testing of returning travellers in response to new threats.  </span></li></ol><p style="margin:0pt 0pt 0pt 10.35pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Donor selection, donation testing and manufacturing all contribute to product safety</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><ol start="8" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 41.6pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The overall approach to safety recognises that b</span><span style="font-family:'Times New Roman'; font-size:11pt">lood, tissues and cells are biomaterials donated freely by one individual and </span><span style="font-family:'Times New Roman'; font-size:11pt">administered to another, and as such </span><span style="font-family:'Times New Roman'; font-size:11pt">carry potential risks of both infection and immunological mis-match with the recipient. Risk mitigation therefore </span><span style="font-family:'Times New Roman'; font-size:11pt">involves a combination of d</span><span style="font-family:'Times New Roman'; font-size:11pt">onor</span><span style="font-family:'Times New Roman'; font-size:11pt"> selection, </span><span style="font-family:'Times New Roman'; font-size:11pt">testing of each donation for infectious agents, manufacturing steps where possible to remove/inactivate pathogens</span><span style="font-family:'Times New Roman'; font-size:11pt"> or</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">white blood</span><span style="font-family:'Times New Roman'; font-size:11pt"> cells</span><span style="font-family:'Times New Roman'; font-size:11pt"> (leucocytes)</span><span style="font-family:'Times New Roman'; font-size:11pt">, matching the blood groups of donor and recipient, and ensuring that the intended donation i</span><span style="font-family:'Times New Roman'; font-size:11pt">s given to the correct patient.   </span><span style="font-family:'Times New Roman'; font-size:11pt">Risk of serious complications is now extremely low, but can never be zero. Monitoring of complications is done through</span><span style="font-family:'Times New Roman'; font-size:11pt"> a system of ‘haemovigilance’ </span><span style="font-family:'Times New Roman'; font-size:11pt">i</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> reporting and analysis of errors, infections and immune complications</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> described in detail below,</span><span style="font-family:'Times New Roman'; font-size:11pt"> and by </span><span style="font-family:'Times New Roman'; font-size:11pt">international </span><span style="font-family:'Times New Roman'; font-size:11pt">horizon scanning for new threats t</span><span style="font-family:'Times New Roman'; font-size:11pt">o the blood supply</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">Blood Services therefore maintain close links with Public Health</span><span style="font-family:'Times New Roman'; font-size:11pt"> organisations</span><span style="font-family:'Times New Roman'; font-size:11pt">.  </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="9" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 41.6pt; padding-left:4.75pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Policies for donor selection include steps to minimis</span><span style="font-family:'Times New Roman'; font-size:11pt">e risk to the do</span><span style="font-family:'Times New Roman'; font-size:11pt">nor and maintain health, so include</span><span style="font-family:'Times New Roman'; font-size:11pt"> frequency of donation</span><span style="font-family:'Times New Roman'; font-size:11pt"> to prevent anaemia</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">as well </span><span style="font-family:'Times New Roman'; font-size:11pt">as consideration of </span><span style="font-family:'Times New Roman'; font-size:11pt">underlying medical cond</span><span style="font-family:'Times New Roman'; font-size:11pt">itions where donation might pose a risk e</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">g</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> epilepsy.  Such policies are subject to review on the basis of new evidence </span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">g</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">f</span><span style="font-family:'Times New Roman'; font-size:11pt">rom other countries</span><span style="font-family:'Times New Roman'; font-size:11pt"> or peer reviewed publications</span><span style="font-family:'Times New Roman'; font-size:11pt">. In</span><span style="font-family:'Times New Roman'; font-size:11pt"> the last 6 years, donation </span><span style="font-family:'Times New Roman'; font-size:11pt">policies have been relaxed by JPAC on upper age limit, diabetes and high blood pressure, but tightened </span><span style="font-family:'Times New Roman'; font-size:11pt">on</span><span style="font-family:'Times New Roman'; font-size:11pt"> weight limit for young </span><span style="font-family:'Times New Roman'; font-size:11pt">female </span><span style="font-family:'Times New Roman'; font-size:11pt">donors (to reduce fainting risk).  NHSBT has initiated a programme of donor health research, beginning with a trial of 50,000 donors to explore personalisation of inter-donation intervals.   </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="10" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">D</span><span style="font-family:'Times New Roman'; font-size:11pt">onor selection to maintain product safety</span><span style="font-family:'Times New Roman'; font-size:11pt"> is underpinned by th</span><span style="font-family:'Times New Roman'; font-size:11pt">e principle of </span><span style="font-family:'Times New Roman'; font-size:11pt">voluntary non-remunerated </span><span style="font-family:'Times New Roman'; font-size:11pt">donation. As donation testing for infecti</span><span style="font-family:'Times New Roman'; font-size:11pt">o</span><span style="font-family:'Times New Roman'; font-size:11pt">us agents cannot be 100% effective, </span><span style="font-family:'Times New Roman'; font-size:11pt">it is important to retain policies which</span><span style="font-family:'Times New Roman'; font-size:11pt"> defer donors with lifestyle factors which increase </span><span style="font-family:'Times New Roman'; font-size:11pt">infection risk </span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">g</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">travel, sexual behaviour,</span><span style="font-family:'Times New Roman'; font-size:11pt"> body piercing. Usually such donors can return after a defined deferral period and/or have their donations tested for additional agents </span><span style="font-family:'Times New Roman'; font-size:11pt">e.g.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">malaria, West Nile virus.  Donors with certain medical conditions </span><span style="font-family:'Times New Roman'; font-size:11pt">e.g.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">cancer are deferred permanently.    These po</span><span style="font-family:'Times New Roman'; font-size:11pt">licies are also subject to review either by SaBTO (</span><span style="font-family:'Times New Roman'; font-size:11pt">e.g</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">MSM deferral changed from lifetime to 12 months) or JPAC (</span><span style="font-family:'Times New Roman'; font-size:11pt">e.g.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">changes to travel deferral in response to changing geography of malaria).</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="11" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt"> Every </span><span style="font-family:'Times New Roman'; font-size:11pt">donation </span><span style="font-family:'Times New Roman'; font-size:11pt">is tested f</span><span style="font-family:'Times New Roman'; font-size:11pt">or virus markers. Traditional tests</span><span style="font-family:'Times New Roman'; font-size:11pt"> often depend on detecting either v</span><span style="font-family:'Times New Roman'; font-size:11pt">iral proteins</span><span style="font-family:'Times New Roman'; font-size:11pt"> or the antibody response produced in an infected individual, but current testing also includes detection of the genetic material of the virus itself (nucleic acid technology, NAT). </span><span style="font-family:'Times New Roman'; font-size:11pt">This is highly sensitive a</span><span style="font-family:'Times New Roman'; font-size:11pt">nd shortens the so-called ‘window period’, when an newly infected individual is infectious to others but does not yet test positive in other tests.  NAT can also detect low level carriers of hepatitis B. </span><span style="font-family:'Times New Roman'; font-size:11pt">Viruses tested for on all donations are HIV (antibod</span><span style="font-family:'Times New Roman'; font-size:11pt">y and NAT), hepatitis B (antigen plus NAT), hepatitis C (antibody plus NAT), and HTLV (antibody).  In addition, travellers returning from endemic areas are tested for malaria, T </span><span style="font-family:'Times New Roman'; font-size:11pt">Cruzi</span><span style="font-family:'Times New Roman'; font-size:11pt"> and West Nile </span><span style="font-family:'Times New Roman'; font-size:11pt">V</span><span style="font-family:'Times New Roman'; font-size:11pt">irus.  Finally, a proportion of whole blood and all plate</span><span style="font-family:'Times New Roman'; font-size:11pt">let donations are tested for cytomegalovirus (CMV)</span><span style="font-family:'Times New Roman'; font-size:11pt">, as this infec</span><span style="font-family:'Times New Roman'; font-size:11pt">tion can cause serious disease in immunosuppr</span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">ssed recipients.  </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="12" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Platelet components carry an additional risk of bacterial infection. In contrast to whole blood/red cells, which are stored </span><span style="font-family:'Times New Roman'; font-size:11pt">at 2-6</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">o</span><span style="font-family:'Times New Roman'; font-size:11pt">C, platelets are stored at 20-22</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">o</span><span style="font-family:'Times New Roman'; font-size:11pt">C to maintain function. Although donor skin is cleaned with an abrasive disinfection technique, a few bacteria may remain, or be present in the donor’s blood, and enter the platelet </span><span style="font-family:'Times New Roman'; font-size:11pt">component</span><span style="font-family:'Times New Roman'; font-size:11pt">.  At the platelet storag</span><span style="font-family:'Times New Roman'; font-size:11pt">e temperature, there is a risk of bacterial growth to a dose which could seriously affect a transfused recipient. All platelet components are therefore tested for bacteria before release to stock, and the cultures maintained till the</span><span style="font-family:'Times New Roman'; font-size:11pt"> end of the</span><span style="font-family:'Times New Roman'; font-size:11pt"> platelet</span><span style="font-family:'Times New Roman'; font-size:11pt"> sh</span><span style="font-family:'Times New Roman'; font-size:11pt">elf life</span><span style="font-family:'Times New Roman'; font-size:11pt"> to detect slow growing organisms.  </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="13" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Donations which test positive on screening are wi</span><span style="font-family:'Times New Roman'; font-size:11pt">thdraw</span><span style="font-family:'Times New Roman'; font-size:11pt">n from the supply, and samples sent to NHSBT’s central microbiology reference laboratory at Colindale (adjacent to Public Health England</span><span style="font-family:'Times New Roman'; font-size:11pt"> [PHE], with whom t</span><span style="font-family:'Times New Roman'; font-size:11pt">here are close links</span><span style="font-family:'Times New Roman'; font-size:11pt">).  There,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">confirmatory testing is carried out to determine whether the positive signal in the screening test was a ‘false positive’</span><span style="font-family:'Times New Roman'; font-size:11pt"> or a true</span><span style="font-family:'Times New Roman'; font-size:11pt"> positive result.  If results are confirmed, the</span><span style="font-family:'Times New Roman'; font-size:11pt"> donor is conta</span><span style="font-family:'Times New Roman'; font-size:11pt">cted for a post-test discussion</span><span style="font-family:'Times New Roman'; font-size:11pt"> with a specialist nurse or doctor</span><span style="font-family:'Times New Roman'; font-size:11pt">. An annual report on donor screening is produced by the joint NHSBT/PHE epidemiology team. </span><span style="font-family:'Times New Roman'; font-size:11pt">The 2012 report can be accessed at </span><a href="http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/BIBD/"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/BIBD/</span></a><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt">.</span></li></ol><p style="margin:0pt 0pt 0pt 10.35pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 0pt 0pt 10.35pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="14" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Certain manufacturing steps also enhance safety. Leucocyte </span><span style="font-family:'Times New Roman'; font-size:11pt">D</span><span style="font-family:'Times New Roman'; font-size:11pt">epletion  (LD, removal of &gt;99% of white blood cells) of all blood </span><span style="font-family:'Times New Roman'; font-size:11pt">components was introduced as a vCJD risk reduction step in 1999, but also reduces the risk of fevers after transfusion, and of transmissi</span><span style="font-family:'Times New Roman'; font-size:11pt">on of certain viruses </span><span style="font-family:'Times New Roman'; font-size:11pt">carried in leucocytes (C</span><span style="font-family:'Times New Roman'; font-size:11pt">ytomegalovirus [CMV] </span><span style="font-family:'Times New Roman'; font-size:11pt">and H</span><span style="font-family:'Times New Roman'; font-size:11pt">uman </span><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt"> cell Lymphotrophic </span><span style="font-family:'Times New Roman'; font-size:11pt">V</span><span style="font-family:'Times New Roman'; font-size:11pt">irus</span><span style="font-family:'Times New Roman'; font-size:11pt">). SaBTO has recommended </span><span style="font-family:'Times New Roman'; font-size:11pt">that </span><span style="font-family:'Times New Roman'; font-size:11pt">for most immunosuppressed</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">individuals, </span><span style="font-family:'Times New Roman'; font-size:11pt">LD provides sufficient CMV safety </span><span style="font-family:'Times New Roman'; font-size:11pt">without the need for testing</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">   </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="15" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt"> For the most immunosuppressed patients, red cells and platelets are irradiated to prevent transfusion-associated graf</span><span style="font-family:'Times New Roman'; font-size:11pt">t-versus-host disease, a universally fatal immune reaction. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="16" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt"> It would </span><span style="font-family:'Times New Roman'; font-size:11pt">be </span><span style="font-family:'Times New Roman'; font-size:11pt">optimal to be able to treat every blood component to kill any pathogens not dete</span><span style="font-family:'Times New Roman'; font-size:11pt">c</span><span style="font-family:'Times New Roman'; font-size:11pt">ted by testing, provided </span><span style="font-family:'Times New Roman'; font-size:11pt">that </span><span style="font-family:'Times New Roman'; font-size:11pt">this were effective for both current and emerging infections, resulted</span><span style="font-family:'Times New Roman'; font-size:11pt"> in no detriment to component function, was free of side-effects in the patient, and was cost effective for the NHS. Commercial manufacturers have worked over the last 10-15 years to develop such systems</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">which have been assessed by the UK Blood Services</span><span style="font-family:'Times New Roman'; font-size:11pt"> a</span><span style="font-family:'Times New Roman'; font-size:11pt">nd </span><span style="font-family:'Times New Roman'; font-size:11pt">considered by </span><span style="font-family:'Times New Roman'; font-size:11pt">SaBTO</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="17" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt"> For FFP and cryoprecipitate, single donations can be treated by a methylene blue</span><span style="font-family:'Times New Roman'; font-size:11pt">/light combination.  This is applied currently to plasma that is imported from Austria for patients born after 1</span><span style="font-family:'Times New Roman'; font-size:7.33pt; vertical-align:super">st</span><span style="font-family:'Times New Roman'; font-size:11pt"> January 1996, importation having b</span><span style="font-family:'Times New Roman'; font-size:11pt">een recommended by SaBTO </span><span style="font-family:'Times New Roman'; font-size:11pt">for this age group which has not been exposed to BSE through diet, </span><span style="font-family:'Times New Roman'; font-size:11pt">as a </span><span style="font-family:'Times New Roman'; font-size:11pt">vCJD </span><span style="font-family:'Times New Roman'; font-size:11pt">risk reduction step.  There is also available a licenced pooled commercial pathogen inactivated FFP, Octaplas (manufactured by Octapharma), which uses a s</span><span style="font-family:'Times New Roman'; font-size:11pt">olvent detergent method to inactivate </span><span style="font-family:'Times New Roman'; font-size:11pt">viruses. This is currently recommended for </span><span style="font-family:'Times New Roman'; font-size:11pt">patients with high exposure to FFP (guidelines of British Committee for Standards in Haematology</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt">).  </span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="18" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Two commercial systems for pathogen inactivation of platelets are CE</span><span style="font-family:'Times New Roman'; font-size:11pt">-marked and have been assessed by the Blood Services.  SaBTO reviewed the topic in 2010 and did not recommend implementation at that time</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt">. On the basis of new evidence, SaBTO conducted a further review which was discussed at its meeting in December 2013; </span><span style="font-family:'Times New Roman'; font-size:11pt">their findings will soon be made public. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Contribution of haemovigilance </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">and horizon scanning to safety</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="19" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">The degree to which the above measures achieve a safe blood supply is monitored through a </span><span style="font-family:'Times New Roman'; font-size:11pt">comprehensive</span><span style="font-family:'Times New Roman'; font-size:11pt"> system</span><span style="font-family:'Times New Roman'; font-size:11pt"> of haemovigilance through which reports of incidents from Blood Services and hospitals are analysed. There are two compl</span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">mentary aspects: the Serious Hazards of Transfusion (SHOT) system was established in 1996 as a voluntary professional organisation, on</span><span style="font-family:'Times New Roman'; font-size:11pt">e of the first national schemes world-wide.  Accountable to the UK Forum and affiliated to the Royal College of Pathologists, it receives reports</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">(&gt;99% from hospitals) of procedural errors, immune reactions and infections</span><span style="font-family:'Times New Roman'; font-size:11pt">, along with near miss events</span><span style="font-family:'Times New Roman'; font-size:11pt">. In i</span><span style="font-family:'Times New Roman'; font-size:11pt">ts annual reports</span><span style="font-family:'Times New Roman'; font-size:11pt"> in which these </span><span style="font-family:'Times New Roman'; font-size:11pt">incidents </span><span style="font-family:'Times New Roman'; font-size:11pt">are analysed,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">SHOT produces specific </span><span style="font-family:'Times New Roman'; font-size:11pt">recommendations to hospitals and Blood Services. </span><span style="font-family:'Times New Roman'; font-size:11pt">SHOT data</span><span style="font-family:'Times New Roman'; font-size:11pt"> have provided evidence to d</span><span style="font-family:'Times New Roman'; font-size:11pt">etermine poli</span><span style="font-family:'Times New Roman'; font-size:11pt">cies for prevention of the most serious transfusion complications</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">e.g.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">use of</span><span style="font-family:'Times New Roman'; font-size:11pt"> male plasma to prevent transfusion-related acute lung injury, the need for bacterial screening of platelets, and a Safer Practice Notice from the National Patient Safety Agency to prevent ABO incompatible transfusions in hospitals.   Although overall repo</span><span style="font-family:'Times New Roman'; font-size:11pt">rting to SHOT continues to increase, life-threatening complication rates have fallen as mitigation steps have been implemented.  </span><span style="font-family:'Times New Roman'; font-size:11pt">Full reports can be found at </span><a href="http://www.shotuk.org"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://www.shotuk.org</span></a><span style="font-family:'Times New Roman'; font-size:11pt">  </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="20" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In addition to SHOT</span><span style="font-family:'Times New Roman'; font-size:11pt">, the MHRA runs the SABRE reporting system </span><span style="font-family:'Times New Roman'; font-size:11pt">which </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">collates</span><span style="font-family:'Times New Roman'; font-size:11pt"> data on serious adverse events and serious adverse reactions relating to blood transfusion, as required by BSQR 2005. </span><span style="font-family:'Times New Roman'; font-size:11pt">  </span></li></ol><p style="margin:0pt 0pt 0pt 36pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="21" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Horizon scanning for new infectious threats is undertaken by a joint NH</span><span style="font-family:'Times New Roman'; font-size:11pt">SBT-PHE epidemiology team, which in turn feeds into JPAC</span><span style="font-family:'Times New Roman'; font-size:11pt">. There are systematic</span><span style="font-family:'Times New Roman'; font-size:11pt"> international</span><span style="font-family:'Times New Roman'; font-size:11pt"> links</span><span style="font-family:'Times New Roman'; font-size:11pt"> through the European Blood Alliance (EBA) Emerging Infectious Disease Monitor information exchange. International practice in blood safety is monitored throu</span><span style="font-family:'Times New Roman'; font-size:11pt">gh </span><span style="font-family:'Times New Roman'; font-size:11pt">UK Blood Services </span><span style="font-family:'Times New Roman'; font-size:11pt">membership of the EBA and </span><span style="font-family:'Times New Roman'; font-size:11pt">NHSBT’s membership of </span><span style="font-family:'Times New Roman'; font-size:11pt">the Alliance of Blood Operators, as well as </span><span style="font-family:'Times New Roman'; font-size:11pt">SHOT’s </span><span style="font-family:'Times New Roman'; font-size:11pt">participation in the International Haemovigilance Network. The UK also has representation on the Council of Europe Steering Committee on</span><span style="font-family:'Times New Roman'; font-size:11pt"> Blood Transfusion (the current Chair of this Committee</span><span style="font-family:'Times New Roman'; font-size:11pt">, Dr Sheila Maclennan</span><span style="font-family:'Times New Roman'; font-size:11pt"> being </span><span style="font-family:'Times New Roman'; font-size:11pt">from the UK, and also the Chair of JPAC </span><span style="font-family:'Times New Roman'; font-size:11pt">), which provides an additional forum for information exchange on blood safety with other European blood services as well as other co</span><span style="font-family:'Times New Roman'; font-size:11pt">untries such as USA, and other organisations such as</span><span style="font-family:'Times New Roman'; font-size:11pt"> the</span><span style="font-family:'Times New Roman'; font-size:11pt"> W</span><span style="font-family:'Times New Roman'; font-size:11pt">orld </span><span style="font-family:'Times New Roman'; font-size:11pt">H</span><span style="font-family:'Times New Roman'; font-size:11pt">ealth </span><span style="font-family:'Times New Roman'; font-size:11pt">O</span><span style="font-family:'Times New Roman'; font-size:11pt">rganisation</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Current virus risk from transfusion</span></p><ol start="22" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:5pt 0pt 7.5pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In the last 5 years, there have been 3 virus transmission incid</span><span style="font-family:'Times New Roman'; font-size:11pt">ents in the UK</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">- one of hepatitis</span><span style="font-family:'Times New Roman'; font-size:11pt"> B (to 2 recipients), one of hepatitis E </span><span style="font-family:'Times New Roman'; font-size:11pt">(an emerging infection for transfusion which has been the subject of an NHSBT-PHE prevalence</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">/</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">look</span><span style="font-family:'Times New Roman'; font-size:11pt">-</span><span style="font-family:'Times New Roman'; font-size:11pt">back study, and which will be reviewed by SaBTO later this year), and one of parvovirus B19, which is rarely tran</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">m</span><span style="font-family:'Times New Roman'; font-size:11pt">itted and not screened for. The joint NHSBT-PHE epidemiology team have calculated the residual risk of a donation infected with HIV, HBV or HCV entering the blood supply. </span><span style="font-family:'Times New Roman'; font-size:11pt">The </span><span style="font-family:'Times New Roman'; font-size:11pt">estimated number of potentially infectious window period donations per million do</span><span style="font-family:'Times New Roman'; font-size:11pt">nations tested that entered the UK blood supply during 2010-2011 was 0.76, 0.036 and 0.15 for HBV, HCV and HIV respectively. At current donation levels of approximately 2.5 million donations each year, testing is estimated to NOT identify approximately two</span><span style="font-family:'Times New Roman'; font-size:11pt"> potentially infectious HBV window period donations every year, one potentially infectious HCV window period donation every 10 years and one potentially infectious HIV window period donation every 2.7 years. More details are available at </span><a href="http://transfusionguidelines.org.uk"><span style="color:#0000ff; font-family:'Times New Roman'; font-size:11pt; text-decoration:underline">http://transfusionguidelines.org.uk</span></a><span style="font-family:'Times New Roman'; font-size:11pt">  </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Matching donor and patient</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="23" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Blood group compatibility between donor and patient</span><span style="font-family:'Times New Roman'; font-size:11pt"> is critical to transfusion safety. The ABO and Rh</span><span style="font-family:'Times New Roman'; font-size:11pt">esus</span><span style="font-family:'Times New Roman'; font-size:11pt"> D blood groups of every donation are tested b</span><span style="font-family:'Times New Roman'; font-size:11pt">y the Blood Services, and hospital</span><span style="font-family:'Times New Roman'; font-size:11pt"> transfusion laboratories</span><span style="font-family:'Times New Roman'; font-size:11pt"> establish the blood group of transfusion recipients. Matching between donor and patient is performed in hospital transfusion laboratories</span><span style="font-family:'Times New Roman'; font-size:11pt">, with complex cases referred to Blood Services</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="24" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">SHOT rep</span><span style="font-family:'Times New Roman'; font-size:11pt">orts have highlighted the issue of errors of donor/patient identity at the bedside. Increasing use of bar code technology has been shown to minimise this risk.  </span><span style="font-family:'Times New Roman'; font-size:11pt">A separate submission from SHOT  will provide more details.</span></li></ol><p style="margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Appropriate Blood Use</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">/Patient </span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Blood Management</span><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps"> is a key contributor to safety</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="25" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">In collaboratio</span><span style="font-family:'Times New Roman'; font-size:11pt">n with Departments of Health, UK Blood Services</span><span style="font-family:'Times New Roman'; font-size:11pt"> have driven programmes to reduce unnecessary use of blood components and provide guidance to the NHS (</span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">g</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">3 Better Blood Transfusion Health S</span><span style="font-family:'Times New Roman'; font-size:11pt">ervice Circulars  in England).  New guidance for Patient Blood Management in England has been approved by the Medical Director for NHS England and will be issued shortly, and NICE has convened a group to produce definitive guidance</span><span style="font-family:'Times New Roman'; font-size:11pt"> on transfusion and its a</span><span style="font-family:'Times New Roman'; font-size:11pt">lternatives in common clinical settings. </span><span style="font-family:'Times New Roman'; font-size:11pt">This has been underpinned by </span><span style="font-family:'Times New Roman'; font-size:11pt">evidence generated from </span><span style="font-family:'Times New Roman'; font-size:11pt">NHSBT </span><span style="font-family:'Times New Roman'; font-size:11pt">and NIHR </span><span style="font-family:'Times New Roman'; font-size:11pt">investment in clinical trials </span><span style="font-family:'Times New Roman'; font-size:11pt">e</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt">g</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">of red cell transfusion in sickle cell disease and gastro-intestinal haemorrhage, and of platelet </span><span style="font-family:'Times New Roman'; font-size:11pt">transfusion</span><span style="font-family:'Times New Roman'; font-size:11pt"> in</span><span style="font-family:'Times New Roman'; font-size:11pt"> haematology patients and trauma. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="26" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Red cell usage </span><span style="font-family:'Times New Roman'; font-size:11pt">in England </span><span style="font-family:'Times New Roman'; font-size:11pt">has fallen from 45 units /1000 population in 2000</span><span style="font-family:'Times New Roman'; font-size:11pt">-01</span><span style="font-family:'Times New Roman'; font-size:11pt"> to 32/1000 population currently.  </span><span style="font-family:'Times New Roman'; font-size:11pt">This trend is seen internationally, as national programmes of Patient Blood Management begin to have an imp</span><span style="font-family:'Times New Roman'; font-size:11pt">act.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">Matching the supply of blood with demand</span></p><p style="margin:0pt; text-align:justify"><span style="color:#000080; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="27" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">We now carefully match blood collections with hospital demand</span><span style="font-family:'Times New Roman'; font-size:11pt"> to prevent shortages and also to minimise outdating (&lt;1%)</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">Some blood groups are in greater need than others, so collecting the right </span><span style="font-family:'Times New Roman'; font-size:11pt">amount of each type of blood is vitally important. We often look to O- and B- blood donors, as well as those with very rare blood types, to donate as frequently as they can.</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> Other donors are important</span><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span><span style="font-family:'Times New Roman'; font-size:11pt"> to us too, but the demand for these blood groups ver</span><span style="font-family:'Times New Roman'; font-size:11pt">sus the number of people who donate makes it easier for us to meet the needs of hospitals.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="28" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Although demand is predicted to fall further over the next 1-2 years, w</span><span style="font-family:'Times New Roman'; font-size:11pt">e will always need to recruit new donors because there will always be people each year </span><span style="font-family:'Times New Roman'; font-size:11pt">who can longer donate for health or other reasons. In England and North Wales for example, we need roughly 200,000 new donors every year to replace those who are no longer able to donate for health or other reasons. </span></li></ol><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><ol start="29" type="1" style="margin:0pt; padding-left:0pt"><li style="font-family:'Times New Roman'; font-size:11pt; margin:0pt 0pt 0pt 46.35pt; text-align:justify; text-indent:0pt"><span style="font-family:'Times New Roman'; font-size:11pt">Due to this careful and multi-face</span><span style="font-family:'Times New Roman'; font-size:11pt">ted management of the blood supply, we have not experienced an acute shortage of</span><span style="font-family:'Times New Roman'; font-size:11pt"> blood for over 5 </span><span style="font-family:'Times New Roman'; font-size:11pt">years.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Strategies to manage both planned events requiring an increase in stock (Olympic Games and Diamond Jubilee) and </span><span style="font-family:'Times New Roman'; font-size:11pt">unplanned disruption (pandemic flu) ha</span><span style="font-family:'Times New Roman'; font-size:11pt">ve meant that no restrictions have had to be placed on hospital activity due to inadequate supplies of blood.</span></li></ol><p style="margin:0pt; text-align:justify"><span style="color:#000080; font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">January 2014</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-variant:small-caps">&#xa0;</span></p><p style="margin:0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p><p style="margin:0pt 18pt 0pt 0pt"><span style="font-family:Arial; font-size:12pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Arial; font-size:10pt"> </span><span style="font-family:Arial; font-size:10pt">http://www.bcshguidelines.com/4_HAEMATOLOGY_GUIDELINES.html</span></p><p style="margin:0pt"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Arial; font-size:10pt"> </span><span style="font-family:Arial; font-size:10pt">https://www.gov.uk/government/policy-advisory-groups/advisory-committee-on-the-safety-of-blood-tissues-and-organs</span></p></body></html>